<DOC>
	<DOCNO>NCT02021669</DOCNO>
	<brief_summary>The purpose 10 week randomize , placebo-controlled , double-blind clinical trial determine whether antidepressant augmentation two gram EPA omega-3 per day superior antidepressant therapy alone major depression patient coronary heart disease ( CHD ) .</brief_summary>
	<brief_title>Omega-3 Depression Other Cardiac Risk Factors - 2</brief_title>
	<detailed_description>Depression increase risk cardiac morbidity mortality 2-4 fold patient coronary heart disease ( CHD ) . Recent clinical trial test standard treatment comorbid depression patient CHD , evaluate effect cardiac morbidity mortality . Most trial show standard treatment modest effect depression produce relatively small difference intervention control condition . Consequently , unable determine whether effective treatment depression improve cardiac outcome . Low dietary intake low plasma phospholipid erythrocyte level two omega-3 fatty acid ( FAs ) , eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) , associate depression cardiac risk marker . There grow evidence small psychiatric trial efficacy standard antidepressant improve coadministration omega-3 FA formulation contain least 1 gram EPA . The purpose propose research determine whether antidepressant augmentation omega-3 formulation superior antidepressant therapy alone major depression patient CHD . The propose study randomize , placebo-controlled , double-blind clinical trial . Consenting patient establish coronary heart disease meet Diagnostic Statistical Manual ( DSM ) -5 criterion major depressive episode undergo baseline evaluation randomly assign receive either 50 mg/day sertraline plus omega-3 FA 50 mg/day sertraline plus placebo 10 week . At baseline 10 week , participant complete assessment depression , 24 hour ambulatory ECG monitoring measure 24 hour heart rate heart rate variability , blood draw measure procoagulant proinflammatory marker blood level EPA , DHA , omega-3 FAs , omega-6 FAs . If sertraline plus omega-3 formulation significantly reduce depression compare sertraline plus placebo , improve least worsen cardiovascular risk marker , study provide strong basis proposing multicenter clinical trial sertraline augment omega-3 determine whether treatment depression improve survival patient CHD depression .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Documented coronary heart disease Diagnosis major depression base structure interview Moderate severe cognitive impairment Meets DSM5 criterion depressive disorder due general medical condition medication Major Axis I psychiatric disorder unipolar depression anxiety disorder , high risk suicide , current substance abuse tobacco ; Not expect survive one year physically unable tolerate study protocol Known sensitivity sertraline omega3 , allergy fish oil shellfish Taking antidepressant omega3 supplement baseline Exempted cardiologist primary care physician Refuses provide inform consent Participating compete protocol trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antidepressive agent</keyword>
	<keyword>Coronary disease</keyword>
	<keyword>Depression</keyword>
	<keyword>Depressive disorder</keyword>
	<keyword>Fatty Acids , Omega-3</keyword>
</DOC>